Prothena reported $-41244000 in Net Income for its second fiscal quarter of 2022.


Ok
Trading Economics members can view, download and compare data from nearly 200 countries, including more than 20 million economic indicators, exchange rates, government bond yields, stock indexes and commodity prices.

The Trading Economics Application Programming Interface (API) provides direct access to our data. It allows API clients to download millions of rows of historical data, to query our real-time economic calendar, subscribe to updates and receive quotes for currencies, commodities, stocks and bonds.

Please Paste this Code in your Website
width
height
Net Income Change
Acadia Pharmaceuticals ACAD:US $ -34.01M 79.04M
Agios Pharmaceuticals AGIO:US $ -91.81M 2.97M
ALKERMES ALKS:US $ -30.14M 5.77M
Alnylam Pharmaceuticals ALNY:US $ -277.4M 37.06M
Amgen AMGN:US $ 1317M 159M
Biogen BIIB:US $ 1058M 754.2M
Biomarin Pharmaceutical BMRN:US $ 27.66M 93.13M
Bluebird Bio BLUE:US $ -100.14M 22.01M
Exelixis EXEL:US $ 70.67M 2.1M
Intercept Pharmaceuticals ICPT:US $ -7.53M 9.76M
Intra Cellular Therapies ITCI:US $ -86.6M 14.48M
IONIS PHARMACEUT IONS:US $ -105.14M 39.97M
Macrogenics MGNX:US $ -41.3M 25.14M
Nektar Therapeutics NKTR:US $ -159.07M 68.68M
Neurocrine Biosciences NBIX:US $ -16.9M 30.8M
Prothena PRTA:US $ -41.24M 4.95M
Regeneron Pharmaceuticals REGN:US $ 852.1M 121.4M
Seattle Genetics SGEN:US $ -134.83M 1.67M
Ultragenyx Pharmaceutical RARE:US $ -158.16M 5.84M
Vertex Pharmaceuticals VRTX:US $ 810.5M 48.4M
Vital Therapies VTL:US $ -21.9M 1.09M
Xoma XOMA:US $ -4670000 2.39M
YTE INCY:US $ 161.43M 123.44M